Compare Box Inc (BOX) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Box Inc vs Summit Therapeutics Inc — how do they compare? Box Inc trades at $32.49 (market cap $4.55B), while Summit Therapeutics Inc trades at $15.2 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 2.7× Box Inc's market cap, and Box Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| BOX | SMMT | |
|---|---|---|
Market Cap | $4.55B | $12.06B |
Sector | Technology | Health |
52-Week High | $33.60 | $26.98 |
52-Week Low | $21.37 | $12.55 |
Enterprise Value | $5.10B | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOX trades at $32.53, down 3.18% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $37.00. Revenue grew to $1.09 billion in 2025 with a net income margin of 22.43%, though the P/E ratio of 51.3 indicates a premium valuation. Recent news highlights Box's partnership with Quintas Energy for an AI-ready content platform, reinforcing its enterprise focus.
The outlook is positive with strong analyst support (60.72% buy ratings) and projected revenue growth to $1.2 billion in 2026. Risks include high valuation multiples and competitive pressures in cloud content management. Upside potential exists if earnings beat expectations, but investors should monitor debt levels and margin sustainability.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Box Inc
Box is a cloud-based content services platform that provides cloud-based storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file sync and sharing provider. More recently, however, the company has focused on bolstering its product portfolio by adding tools such as governance and e-signature that enhance workflow management and collaboration.
Read more on BOX →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
